AI Stock Memo: ABUS - Arbutus Biopharma - RankAlpha

ABUS

Rating buyAI Memo

Arbutus Biopharma

As of 2026-03-26/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-03-26 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Next quarterly results / corporate update (Q1 2026) • 2026-06-24

Expected move: +25%

Biggest risk

Delay in program progress, larger-than-expected cash burn, or a dilutive financing at unfavorable terms would push valuation below current levels toward the bear target.

Invalidation

Break below $3 or thesis failure.

What would change my mind?

Positive readouts/cost reductions or a value-accretive partnership/financing at favorable terms could re-rate shares toward higher analyst highs and specialist takeover/partner interest, supporting the bull target.

Research note

Recommendation

buy

Confidence

medium

As of

2026-03-26

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Next quarterly results / corporate update (Q1 2026)
Balance-sheet-driven financing or partnering decision within 12 months
Positive readouts/cost reductions or a value-accretive partnership/financing at favorable terms could re-rate shares toward higher analyst highs and specialist takeover/partner interest, supporting the bull target.

BearKey bullets

Clinical/program delays or negative data
Dilutive financing at unfavorable terms
Partnering negotiations fail or are unfavorable

WatchKey bullets

ANCHOR: {"price": 4.46, "timestamp_utc": "2026-03-26T13:02:06+00:00", "source": "broker_last"} ANALYST_TARGETS_REVIEWED: true Analyst median (~$5.68) aligns with our base target; our bull target tracks the analyst high ($7.35) while the bear reflects a dilution/runway-hit scenario.

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $6 (p=50%)

Bull/Bear spread: +61% / -34%

Vs latest close: Bull +61% · Base +25% · Bear -34%

Scenario probabilities

Bull Target: $7 (p=25%)Base Target: $6 (p=50%)Bear Target: $3 (p=25%)

Commentary

Recent corporate update and Q4/2025 results refreshed focus on cash runway and corporate strategy; coverage tone is cautiously constructive given limited near-term program catalysts and a modest analyst target range [#8-K-2026-03-23] [#PR-undated]. Market commentary emphasizes financing/partnering as the pivotal near-term call [#SERP-3].

As of 2026-03-26 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Delay in program progress, larger-than-expected cash burn, or a dilutive financing at unfavorable terms would push valuation below current levels toward the bear target.

Drivers

Scannable catalysts and supporting factors

Next quarterly results / corporate update (Q1 2026)
Balance-sheet-driven financing or partnering decision within 12 months

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-03-26Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$5.68

Range (USD)

$4.50 - $7.35

Count

Query: Arbutus Biopharma Corp Common (ABUS) analyst consensus price target high low average

Arbutus Biopharma Corporation: Target Price Consensus and ...
Search result #1
Chardan Research Adjusts Price Target on Arbutus Biopharma to $5 From $4.50, Maintains Buy Rating · HC Wainwright Trims Price Target on Arbutus Biopharma to $5 ...
Extracted: $5.00, $4.50Open source
ABUS | Arbutus Biopharma Corporation Common Analyst Forecasts
Search result #2
Based on 1 Wall Street analysts offering price targets for ABUS in the last 6 months. The median price target is $5.00 with a high estimate of $5.00 and a ...
Extracted: $5.00Open source
ABUS Forecast, Price Target & Analyst Ratings - ChartMill
Search result #3
9 analysts have analysed ABUS and the average price target is 5.78 USD. This implies a price increase of 27.59% is expected in the next year compared to the ...
Extracted: $5.78Open source
Arbutus Biopharma (ABUS) Stock Forecast & Price Target
Search result #4
According to projections from 3 analysts, the average 12-month price target for Arbutus Biopharma is 5.681 USD, with a high estimate of 7.02395689 USD and a low ...
Extracted: $5.68, $7.02Open source
ABUS Price: Quote, Forecast, Charts & News - Perplexity
Search result #5
Arbutus Biopharma shares closed modestly higher at $4.67, up 0.21%, holding steady amid a volatile session for the broader market. The biotechnology stock ...
Extracted: $4.67Open source
ABUS Analyst Ratings for Arbutus Biopharma Corp Stock - Barchart ...
Search result #6
... Analyst Target Prices. HIGH TARGET. MEAN TARGET. LOW TARGET. 52 WK High. 52 WK Low. Average Analyst Ratings. 3 Mths Ago. Moderate Buy. 4.20. Based on 5 analysts.
Open source

Scenarios

Bull Target (Scenario probability)

$7 / p=25% prob

Base Target (Scenario probability)

$6 / p=50% prob

Bear Target (Scenario probability)

$3 / p=25% prob

Price $5 as of 2026-05-29

Nearest Scenario: Base (∆ 25%)

Targets vs latest close: Bull +61% · Base +25% · Bear -34%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Short-term Catalysts

Next few weeks

Next quarterly results / corporate update (Q1 2026)
2026-06-24
Market will re-price on Q1 2026 operational/financial detail and management commentary following the Q4/2025 release; investors should watch cash/runway commentary and program updates referenced in the March 23, 2026 corporate update [#8-K-2026-03-23].
Prob 80% • Move 8% • Priced-in 40%

Long-term Catalysts

Months to a year

Balance-sheet-driven financing or partnering decision within 12 months
2027-03-26
Arbutus reported cash, cash equivalents and marketable securities of ~$91.5M at year-end 2025 per the March 23, 2026 release; that runway math makes a financing, partnership, or explicit runway-extension plan the likely company action within the next year, which would materially affect valuation [#8-K-2026-03-23] [#PR-undated].
Prob 65% • Move 35% • Priced-in 30%

Risks

Clinical/program delays or negative data
Dilutive financing at unfavorable terms
Partnering negotiations fail or are unfavorable
Regulatory or manufacturing setbacks

Peers

Symbol	Summary
TBPH	Similar mid-cap biopharma with clinical-stage programs and comparable market cap; useful comparator for financing/valuation dynamics.
ESPR	Small-cap specialty biopharma with commercialization/partnering history; relevant for assessing partnership outcomes and cash-runway responses.
ELVN	Clinical-stage biotech of similar market cap and development financing profile; helps calibrate program-risk premium.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Arbutus Biopharma Corp Common (ABUS) analyst consensus price target high low average
Analysis date: 2026-03-26